Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.

06/18/2026, 1:00 PM • GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics (4DMT) announced that management will present at three major investor conferences in March 2026: TD Cowen Health Care Conference (March 3), Leerink Global Healthcare Conference (March 10), and Barclays Global Healthcare Conference (March 12). The company is advancing late-stage biotech therapeutics including 4D-150 for retinal vascular diseases currently in Phase 3 development and 4D-710 for cystic fibrosis.

02/19/2026, 8:00 AM • GlobeNewswire

4DMT Appoints Kristian Humer as Chief Financial Officer

4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.

11/17/2025, 6:00 AM • GlobeNewswire

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4D Molecular Therapeutics partnered with Otsuka Pharmaceutical to develop and commercialize 4D-150, a potential transformative therapy for retinal vascular diseases in the Asia-Pacific region, receiving $85 million upfront and potential milestone payments up to $336 million.

10/30/2025, 11:02 PM • GlobeNewswire

GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer

GenVivo appointed Dr. Noriyuki Kasahara as Chief Scientific Officer to advance its genetic therapy platform for cancer treatment, leveraging his extensive experience in gene therapy and vector technology research.

09/11/2025, 6:00 AM • GlobeNewswire

4dMT Revenue Jumps 200 Percent in Q2

4D Molecular Therapeutics reported Q2 2025 financial results with $15 million revenue, exceeding estimates, driven by collaboration income. The company advanced its gene therapy programs for retinal and respiratory diseases, with promising clinical trial progress and a workforce reduction to manage expenses.

08/11/2025, 8:16 AM • The Motley Fool

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT reported Q2 2025 financial results, highlighting accelerated Phase 3 clinical trials for 4D-150 in wet AMD and DME, positive 60-week trial results, and a workforce reduction to drive late-stage execution with $417 million cash runway into 2028.

08/11/2025, 8:00 AM • GlobeNewswire

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

4D Molecular Therapeutics will present interim results from two clinical trials evaluating 4D-150, a potential treatment for diabetic macular edema and neovascular age-related macular degeneration, at the ASRS Annual Scientific Meeting in July 2025.

07/24/2025, 8:00 AM • GlobeNewswire